OKYO Pharma Limited (OKYO), a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain or NCP and inflammatory dry eye disease or DED, announced on Wednesday that it has received $1.4 million in non-dilutive funding.
This financial support will be used to advance the company's research and development efforts, particularly its lead program, OK-101, which is focused on treating NCP, a condition with no FDA-approved therapy.
The funding strengthens OKYO Pharma's ability to progress its innovative pipeline without diluting shareholder value. It will help further the development of OK-101, which is currently being evaluated in Phase 2 trials for both NCP and DED.
"We are excited to secure this funding, which supports our mission to develop groundbreaking treatments for ophthalmic diseases," said Dr. Gary S. Jacob, CEO of OKYO Pharma. "This financial boost allows us to continue advancing our clinical programs and creating value for our shareholders."
Currently, OKYO is trading at $1.06.
For comments and feedback: editorial@rttnews.com